Essilor buys majority stake in Transitions Optical

Article

Essilor International has acquired PPG Industries’ 51% stake in Transitions Optical.

 

Pinellas Park, FL-PPG Industries and Essilor International have struck a deal for Essilor to acquire PPG Industries’ 51% stake in Transitions Optical, according to news releases from PPG and Essilor. Essilor has held a 49% share of Transitions Optical since the business was founded in 1990.

Dave Cole, president, Transitions Optical, noted the history that PPG and Essilor have with Transitions: “We look forward to a continued strong relationship with PPG, because they will be providing ongoing research and development services and optical dyes to Transitions Optical under multi-year agreements with Essilor.

“This transaction is a continuation and enhancement of a relationship that has brought value to us and to our industry. There are tremendous opportunities to boost expansion of photochromic products, particularly in fast-growing markets,” Cole added.

The transaction is projected to close in the first half of 2014. Until then, it will be business as usual, Cole said. Transitions Optical will continue as a separately managed and operated business. According to the company, supplies of Transitions lenses will not be affected, and will continue to be available through other lens manufacturers.

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.